Continuidad asistencial entre cardiología y AP en pacientes con cardiopatía isquémica crónica: diseño del estudio CAPRICI

Abstract

Introduction and objectives

The management of cardiovascular risk factors (CVRF) should be conducted in Primary Care, which is particularly crucial for patients with prior cardiovascular disease. A semi-annual follow-up, aligned with the guidelines of clinical practice and coinciding with the administration of an injectable drug like inclisiran, could enhance healthcare efficiency. The CAPRICI study aims to analyze whether the implementation of a follow-up program, with semi-annual visits parallel to the administration of inclisiran in Primary Care, in patients with chronic ischemic heart disease, allows for optimized follow-up and improved control of CVRF.

Methods

The CAPRICI study is a randomized, controlled, prospective, multicenter trial involving 5 health centers in the Health Area of Santiago de Compostela and Barbanza: A Estrada, Concepción Arenal, Ribeira, Melide, and Milladoiro. The study will include patients with chronic coronary disease associated with other pathologies that increase cardiovascular risk, with elevated levels of low-density lipoprotein cholesterol (> 100 mg/dl) despite conventional treatment with high-potency statins, with or without ezetimibe. The number of visits to healthcare services, as well as the control of CVRF and lifestyle habits, will be recorded.

Conclusions

The results of this study will contribute to improving the knowledge about the care of patients at very high cardiovascular risk, particularly in optimizing the number of visits and hospital referrals, as well as in the control of their CVRF.

Clinicaltrials.gov identifier: NCT06421363